A Phase 2 interventional study of DM199 in Kidney Diseases, sponsored by DiaMedica Therapeutics Inc. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by DiaMedica Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 93 under way, 15 of them phase 3. Kidney Diseases · United States.
Among the 416 studies in Kidney Diseases with a site in United States, this one is the 122nd largest by enrollment of the 318 interventional ones that give a count, is one of 22 that started in 2019, is one of 67 in phase 2, and was the 288th registered.
970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.
Browse Kidney Diseases studies →64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Geisinger Clinic · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
416 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 87 · Phase 3 63 · Phase 4 24
First in 1976; this study’s year is marked. 22 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 64 across 647 interventional studies indexed under Kidney Diseases.
Median enrollment 50 across the 318 interventional studies, 226 across the 93 observational. Of the 295 that completed or were terminated, 126 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 416 have an industry lead sponsor. The 10 most frequent:
DiaMedica Therapeutics Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
DiaMedica Therapeutics Inc has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
27 of the studies in Kidney Diseases with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05696613Phase 3Cerium Pharmaceuticals, Inc.A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy | 2027-04-01 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT05153967Vanderbilt University Medical CenterCooperative Assessment of Late Effects for SCD Curative Therapies | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 416 studies in Kidney Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts.
Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension
Participants in each cohort will be enrolled in a parallel assignment to one of two doses:
Dose 1: DM199 2.0 µg/kg SC 2x week for 95 days Dose 2: DM199 5.0 µg/kg SC 2x week for 95 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort I
Cohort II
Cohort III
Both Cohorts
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
Drug: DM199
n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
Drug: DM199
A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
Safety as Assessed by Incidence, Severity and Causality of AEs
The safety population includes all participants who received at least one dose of the study intervention and were evaluated for safety outcomes. Data are summarized using this population to provide a comprehensive assessment of treatment-related adverse events, tolerability, and overall safety, ensuring consistent interpretation of safety findings across study groups.
Time frame: From initial dose (Day 1) through Day 104
Estimated Glomerular Filtration Rate (eGFR), Change From Baseline
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, and eGFR measurements were obtained at baseline and every two weeks through week 16. This longitudinal assessment allowed for the evaluation of trends, stability, or potential treatment-related effects on kidney function, providing important clinical context for interpreting the study outcomes and the overall renal safety profile of the study population.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
Urine Albumin to Creatinine Ratio (UACR), Change From Baseline
Urine albumin-to-creatinine ratio (UACR) was assessed as a measure of urinary albumin excretion and kidney health throughout the 16-week period. UACR was calculated from spot urine samples by dividing the urine albumin concentration by the urine creatinine concentration, providing a standardized assessment that minimizes the impact of urine dilution. Measurements were obtained at predefined study visits to evaluate changes from baseline and to monitor the effects of treatment on albuminuria over time. UACR is a clinically relevant marker of kidney damage and disease progression, with higher values generally indicating greater renal impairment and increased risk of adverse kidney and cardiovascular outcomes. Longitudinal assessment of UACR provided important information regarding treatment response, renal function preservation, and the overall kidney-related effects of the study intervention. Note: UACR values are reported in g/kg, which is equivalent to mg/g.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
Systolic Blood Pressure, Change From Baseline
Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.
Time frame: Baseline, Day 4 through Day 95
Diastolic Blood Pressure, Change From Baseline
Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.
Time frame: Baseline, Day 4 through Day 95
Urine KLK1 Concentration Pre and Post DM199 Administration
Observed urine concentration of KLK1 throughout the treatment period.
Time frame: Baseline through Day 104
Plasma KLK1 Concentration Pre and Post DM199 Administration
Observed KLK1 concentration throughout the treatment period.
Time frame: Baseline through Day 104
Tumor Necrosis Factor Receptor 1 (TNF-R1) Concentration in Plasma, Change From Baseline
Tumor Necrosis Factor Receptor 1 (TNF-R1) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
Time frame: Baseline, Weeks 4, 8, 12, and 14
C-Reactive Protein (CRP) Concentration in Plasma, Change From Baseline
C-Reactive Protein (CRP) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Matrix Metalloproteainase-9 (MMP-9) Concentration in Plasma, Change From Baseline
Matrix Metalloproteainase-9 (MMP-9) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Matrix Metalloproteinase-9 (MMP-9) was measured throughout the treatment period as a biomarker of extracellular matrix remodeling, inflammation, and tissue injury. MMP-9 is a member of the matrix metalloproteinase family of enzymes that degrade components of the extracellular matrix and play a critical role in physiological and pathological processes, including wound healing, immune cell migration, vascular remodeling, fibrosis, and inflammatory responses. Elevated MMP-9 levels have been associated with various disease states, including chronic kidney disease, cardiovascular disease, inflammatory disorders, and conditions characterized by tissue damage and remodeling.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Vascular Endothelial Growth Factor (VEGF) Concentration in Plasma, Change From Baseline
Vascular Endothelial Growth Factor (VEGF) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Cystatin C Concentration in Plasma, Change From Baseline
Cystatin C concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Prostaglandin E2 Concentration in Plasma, Change From Baseline
Prostaglandin E2 concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostaglandin E2 is a biomarker of inflammatory activity, immune regulation, and physiological processes involved in vascular and renal function. PGE2 is a bioactive lipid mediator derived from arachidonic acid through the cyclooxygenase (COX) pathway and is produced by a variety of cell types in response to inflammatory stimuli, tissue injury, and other physiological signals. PGE2 plays an important role in modulating inflammation, vasodilation, blood flow regulation, immune responses, and maintenance of normal kidney function.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Prostacyclin Concentration in Plasma, Change From Baseline
Prostacyclin concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostacyclin is a biomarker of vascular function, endothelial health, and regulation of platelet activity. Prostacyclin, also known as prostaglandin I2 (PGI2), is a biologically active lipid mediator produced primarily by vascular endothelial cells through the cyclooxygenase pathway. It plays a critical role in maintaining vascular homeostasis by promoting vasodilation, inhibiting platelet aggregation, and helping to regulate blood flow and vascular tone. Prostacyclin is also involved in modulating inflammatory responses and protecting against the development of thrombosis and vascular injury.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Kidney Injury Molecule-1 (KIM-1) Concentration in Urine, Change From Baseline
Kidney Injury Molecule-1 (KIM-1) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.
Time frame: Baseline, Weeks 4, 8, 12, and 14
Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration in Urine, Change From Baseline
Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.
Time frame: Baseline, Weeks 4, 8, 12, and 14
| Milestone | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 13 | 12 | 18 | 17 |
| Completed | 8 | 7 | 13 | 10 | 15 | 15 |
| Not completed | 4 | 5 | 0 | 2 | 3 | 2 |
The safety population includes all participants who received at least one dose of the study intervention and were evaluated for safety outcomes. Data are summarized using this population to provide a comprehensive assessment of treatment-related adverse events, tolerability, and overall safety, ensuring consistent interpretation of safety findings across study groups.
| Participants | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| TEAE | 7 | 10 | 7 | 8 | 6 | 10 |
| TEAE: Mild | 2 | 6 | 2 | 3 | 4 | 4 |
| TEAE: Moderate | 3 | 3 | 5 | 5 | 0 | 3 |
| TEAE: Severe | 2 | 1 | 0 | 0 | 2 | 3 |
| TEAE: Related | 1 | 5 | 2 | 6 | 3 | 4 |
| TEAE: Unrelated | 6 | 5 | 5 | 2 | 3 | 6 |
| Serious TEAE | 2 | 1 | 2 | 0 | 2 | 4 |
| TEAE Leading to Study Discontinuation | 0 | 1 | 0 | 0 | 0 | 0 |
| TEAE Leading to Death | 0 | 1 | 0 | 0 | 0 | 0 |
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, and eGFR measurements were obtained at baseline and every two weeks through week 16. This longitudinal assessment allowed for the evaluation of trends, stability, or potential treatment-related effects on kidney function, providing important clinical context for interpreting the study outcomes and the overall renal safety profile of the study population.
| mL/min/1.73m^2 | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 2 | 0.21 ± 6.971 | -2.34 ± 6.628 | 2.46 ± 4.194 | 6.73 ± 12.901 | -3.82 ± 11.488 | -5.39 ± 15.411 |
| Week 4 | 0.82 ± 6.405 | -1.39 ± 6.309 | 1.95 ± 6.270 | -1.62 ± 4.398 | 0.37 ± 5.687 | -2.91 ± 7.405 |
| Week 6 | -0.51 ± 6.459 | -0.64 ± 7.051 | 2.43 ± 7.378 | 1.56 ± 4.441 | -1.48 ± 7.512 | -0.51 ± 7.922 |
| Week 8 | -3.05 ± 4.121 | -3.34 ± 6.498 | 3.98 ± 6.255 | -2.42 ± 5.812 | -1.88 ± 6.015 | -1.44 ± 7.948 |
| Week 10 | 0.91 ± 4.302 | -1.63 ± 8.966 | 2.59 ± 5.001 | 3.35 ± 5.575 | 2.43 ± 6.668 | 2.35 ± 12.282 |
| Week 12 | 2.68 ± 10.157 | -2.81 ± 7.390 | 2.83 ± 8.114 | 0.30 ± 4.171 | 3.94 ± 10.434 | 0.16 ± 5.883 |
| Week 14 | 1.20 ± 8.307 | -1.08 ± 7.536 | 2.82 ± 6.300 | -2.78 ± 4.193 | 3.03 ± 7.857 | 1.23 ± 5.276 |
| Week 16 | -1.29 ± 4.771 | -1.37 ± 7.117 | 3.62 ± 5.989 | 1.22 ± 4.669 | 0.97 ± 8.365 | -1.09 ± 7.705 |
Urine albumin-to-creatinine ratio (UACR) was assessed as a measure of urinary albumin excretion and kidney health throughout the 16-week period. UACR was calculated from spot urine samples by dividing the urine albumin concentration by the urine creatinine concentration, providing a standardized assessment that minimizes the impact of urine dilution. Measurements were obtained at predefined study visits to evaluate changes from baseline and to monitor the effects of treatment on albuminuria over time. UACR is a clinically relevant marker of kidney damage and disease progression, with higher values generally indicating greater renal impairment and increased risk of adverse kidney and cardiovascular outcomes. Longitudinal assessment of UACR provided important information regarding treatment response, renal function preservation, and the overall kidney-related effects of the study intervention. Note: UACR values are reported in g/kg, which is equivalent to mg/g.
| g/kg | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 2 | -284.70 ± 703.650 | -27.51 ± 290.362 | 212.32 ± 578.047 | 23.72 ± 287.870 | -52.93 ± 454.635 | -122.62 ± 598.592 |
| Week 4 | -69.58 ± 227.248 | -64.40 ± 213.027 | 280.03 ± 925.341 | -117.77 ± 186.531 | 300.85 ± 1231.140 | -164.76 ± 629.004 |
| Week 6 | -368.82 ± 710.979 | -46.39 ± 211.168 | 507.61 ± 1156.361 | 17.37 ± 447.865 | 512.44 ± 1155.188 | -57.55 ± 585.035 |
| Week 8 | -121.49 ± 306.689 | 91.61 ± 320.425 | 344.88 ± 1106.909 | 0.43 ± 407.291 | 348.58 ± 1067.792 | 208.26 ± 903.591 |
| Week 10 | -425.72 ± 723.899 | 20.91 ± 274.051 | 361.47 ± 1115.104 | -43.38 ± 281.221 | 152.62 ± 636.389 | -439.69 ± 1416.742 |
| Week 12 | -340.30 ± 621.339 | -22.04 ± 220.814 | 472.15 ± 1275.223 | -121.54 ± 298.325 | 436.20 ± 850.279 | 299.60 ± 1098.347 |
| Week 14 | -421.26 ± 779.831 | -152.32 ± 229.611 | 357.03 ± 1143.252 | -10.61 ± 226.721 | 530.53 ± 1151.726 | 300.85 ± 836.208 |
| Week 16 | -331.20 ± 853.633 | 41.17 ± 439.579 | 174.37 ± 1171.124 | -202.90 ± 327.738 | 498.97 ± 1100.819 | 98.40 ± 1002.859 |
Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.
| mmHg | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Day 4 | 7.5 ± 31.87 | 6.3 ± 14.91 | 7.2 ± 14.23 | 5.8 ± 13.18 | -1.5 ± 15.50 | 0.7 ± 18.80 |
| Week 2 - Day 8 | 11.2 ± 33.03 | -1.0 ± 21.85 | 8.5 ± 17.31 | 6.5 ± 15.72 | -4.5 ± 13.06 | -1.7 ± 13.16 |
| Week 2 - Day 11 | 13.1 ± 43.62 | -3.1 ± 12.63 | 8.2 ± 9.96 | 6.1 ± 12.52 | -1.6 ± 13.52 | -7.4 ± 13.39 |
| Week 3 - Day 15 | 3.7 ± 26.75 | -1.0 ± 16.31 | 4.9 ± 10.96 | 1.8 ± 13.64 | -1.6 ± 14.69 | -6.3 ± 15.10 |
| Week 3 - Day 18 | -1.1 ± 27.34 | -4.2 ± 14.89 | 7.8 ± 10.41 | 10.1 ± 22.01 | 0.9 ± 15.49 | -6.2 ± 17.31 |
| Week 4 - Day 22 | -6.0 ± 22.30 | -2.4 ± 16.60 | 2.0 ± 9.53 | 2.2 ± 12.06 | -5.8 ± 12.36 | 1.3 ± 19.35 |
| Week 4 - Day 25 | 12.4 ± 40.12 | -7.9 ± 12.76 | 0.1 ± 9.73 | -0.8 ± 12.43 | -0.5 ± 11.35 | -3.6 ± 14.86 |
| Week 5 - Day 29 | 1.4 ± 30.51 | -0.5 ± 17.26 | 1.6 ± 11.98 | 0.5 ± 10.35 | -2.1 ± 14.66 | -7.5 ± 15.36 |
| Week 5 - Day 32 | 11.2 ± 38.50 | -5.8 ± 18.29 | -0.2 ± 9.85 | 5.7 ± 16.17 | -3.6 ± 11.17 | -0.3 ± 14.24 |
| Week 6 - Day 36 | 4.5 ± 33.57 | -9.1 ± 11.86 | -0.6 ± 19.15 | 2.9 ± 9.22 | -1.5 ± 14.41 | 2.6 ± 13.90 |
| Week 6 - Day 39 | 8.7 ± 33.88 | -6.2 ± 18.81 | -1.7 ± 12.77 | 3.8 ± 13.76 | -3.5 ± 10.32 | -3.2 ± 15.14 |
| Week 7 - Day 43 | -4.0 ± 28.41 | -2.9 ± 17.91 | -2.1 ± 13.22 | 0.1 ± 12.20 | -6.3 ± 14.93 | -5.2 ± 15.16 |
| Week 7 - Day 46 | 5.5 ± 39.95 | -7.8 ± 19.04 | 1.0 ± 18.23 | 0.6 ± 8.36 | -2.3 ± 14.32 | 4.2 ± 15.86 |
| Week 8 - Day 50 | -17.5 ± 29.16 | -6.0 ± 16.16 | 3.6 ± 7.81 | 1.4 ± 14.45 | -3.1 ± 15.53 | -0.4 ± 15.27 |
| Week 8 - Day 53 | -19.6 ± 33.30 | -9.7 ± 19.66 | 1.4 ± 15.05 | 0.1 ± 8.48 | -10.5 ± 13.30 | -2.5 ± 19.31 |
| Week 9 - Day 57 | -5.6 ± 27.77 | -0.1 ± 20.15 | -2.2 ± 17.78 | -0.8 ± 14.05 | -4.1 ± 18.48 | -0.5 ± 25.18 |
| Week 9 - Day 60 | -15.3 ± 26.04 | -6.0 ± 14.59 | -0.2 ± 18.53 | 7.1 ± 12.95 | -1.6 ± 23.49 | 4.6 ± 22.32 |
| Week 10 - Day 64 | -14.2 ± 36.95 | -6.4 ± 18.15 | -0.2 ± 11.31 | -3.7 ± 20.51 | -4.8 ± 13.97 | 5.3 ± 19.37 |
| Week 10 - Day 67 | -10.2 ± 31.66 | -2.1 ± 26.08 | -1.1 ± 16.99 | 2.6 ± 12.59 | -2.1 ± 17.41 | 0.9 ± 18.54 |
| Week 11 - Day 71 | -14.9 ± 28.12 | -1.4 ± 18.51 | 1.9 ± 18.59 | 0.4 ± 9.40 | -2.6 ± 18.89 | 5.1 ± 21.95 |
| Week 11 - Day 74 | -17.8 ± 31.60 | -1.1 ± 15.86 | 3.5 ± 20.30 | 1.6 ± 10.60 | -5.4 ± 11.53 | 5.2 ± 21.13 |
| Week 12 - Day 78 | -17.2 ± 27.49 | -6.1 ± 18.64 | 6.8 ± 14.29 | 2.9 ± 13.42 | -4.0 ± 13.97 | -3.1 ± 18.63 |
| Week 12 - Day 81 | -11.2 ± 26.74 | -4.1 ± 18.51 | 1.8 ± 18.08 | -0.7 ± 14.79 | -6.1 ± 14.07 | 1.3 ± 22.37 |
| Week 13 - Day 85 | -16.8 ± 30.46 | -9.7 ± 14.90 | -0.7 ± 15.43 | 2.6 ± 8.68 | -3.9 ± 18.70 | 0.8 ± 14.17 |
| Week 13 - Day 88 | -13.1 ± 32.82 | -8.3 ± 20.21 | -1.0 ± 8.43 | 1.7 ± 11.55 | -4.5 ± 17.84 | 1.7 ± 18.81 |
| Week 14 - Day 92 | -17.4 ± 34.44 | -4.9 ± 13.80 | 3.5 ± 13.05 | 2.8 ± 10.11 | -4.5 ± 18.80 | 0.4 ± 15.08 |
| Week 14 - Day 95 | -16.6 ± 34.26 | -2.4 ± 17.23 | -1.4 ± 11.77 | 0.3 ± 11.65 | -9.2 ± 11.51 | 3.5 ± 16.37 |
Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.
| mmHg | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Day 4 | 1.5 ± 11.01 | 0.6 ± 7.09 | 5.8 ± 10.58 | 7.5 ± 9.81 | -4.2 ± 7.94 | 0.7 ± 12.97 |
| Week 2 - Day 8 | 0.5 ± 16.16 | -3.7 ± 10.34 | 6.4 ± 11.41 | 5.3 ± 11.16 | 1.9 ± 8.50 | 1.1 ± 9.34 |
| Week 2 - Day 11 | 4.1 ± 20.16 | 0.0 ± 8.40 | 4.6 ± 8.85 | 7.9 ± 8.28 | 0.9 ± 8.08 | -0.8 ± 7.64 |
| Week 3 - Day 15 | -3.5 ± 10.31 | -0.6 ± 11.61 | 1.4 ± 11.67 | 2.8 ± 11.87 | 1.8 ± 7.99 | 0.4 ± 10.48 |
| Week 3 - Day 18 | -10.9 ± 9.27 | -4.5 ± 13.66 | 3.5 ± 11.23 | 4.5 ± 12.34 | 0.3 ± 7.64 | -2.8 ± 9.15 |
| Week 4 - Day 22 | -1.7 ± 8.35 | -2.1 ± 12.27 | -0.3 ± 10.44 | 3.5 ± 5.99 | -1.3 ± 8.43 | -0.4 ± 7.00 |
| Week 4 - Day 25 | -3.2 ± 15.19 | -7.4 ± 11.51 | -1.1 ± 10.96 | -0.4 ± 7.14 | 0.1 ± 6.80 | 2.4 ± 10.41 |
| Week 5 - Day 29 | -3.3 ± 18.26 | -1.4 ± 8.53 | 3.2 ± 12.28 | 1.4 ± 11.32 | -0.6 ± 9.43 | -0.1 ± 13.85 |
| Week 5 - Day 32 | 1.3 ± 19.81 | -4.2 ± 15.34 | 1.1 ± 8.85 | 5.8 ± 11.96 | -0.3 ± 11.27 | 0.2 ± 11.55 |
| Week 6 - Day 36 | -1.9 ± 16.66 | -5.8 ± 11.52 | 0.0 ± 10.15 | 3.6 ± 8.96 | 2.2 ± 6.47 | 1.9 ± 9.93 |
| Week 6 - Day 39 | -10.0 ± 15.81 | -2.2 ± 12.71 | -1.3 ± 9.18 | 3.5 ± 9.54 | -0.8 ± 9.45 | 0.3 ± 11.39 |
| Week 7 - Day 43 | -8.0 ± 10.11 | -3.3 ± 10.98 | -1.6 ± 8.13 | 3.1 ± 9.33 | 0.1 ± 9.14 | -2.1 ± 11.21 |
| Week 7 - Day 46 | -6.9 ± 15.70 | -2.2 ± 10.76 | -2.4 ± 13.65 | 1.8 ± 8.95 | 1.6 ± 8.22 | 1.9 ± 8.51 |
| Week 8 - Day 50 | -6.6 ± 21.67 | -1.6 ± 11.04 | -0.1 ± 8.03 | -0.2 ± 9.50 | 1.1 ± 7.50 | 0.9 ± 7.49 |
| Week 8 - Day 53 | -14.8 ± 18.19 | -3.2 ± 13.07 | -2.8 ± 9.41 | 0.4 ± 10.83 | -2.5 ± 6.64 | -2.7 ± 10.13 |
| Week 9 - Day 57 | -6.4 ± 17.12 | -3.7 ± 9.74 | 0.8 ± 13.53 | 0.5 ± 9.61 | -1.5 ± 10.81 | -1.6 ± 6.60 |
| Week 9 - Day 60 | -13.1 ± 15.38 | -4.9 ± 8.54 | 1.5 ± 11.28 | 6.2 ± 11.04 | 0.0 ± 11.67 | 3.8 ± 10.91 |
| Week 10 - Day 64 | -14.4 ± 16.18 | -4.6 ± 8.26 | -0.1 ± 8.74 | 1.3 ± 16.40 | -0.8 ± 7.01 | -0.1 ± 10.94 |
| Week 10 - Day 67 | -17.2 ± 15.50 | -2.3 ± 11.94 | 1.9 ± 13.79 | 4.0 ± 14.10 | 0.8 ± 7.76 | 1.9 ± 10.96 |
| Week 11 - Day 71 | -13.6 ± 17.66 | 0.7 ± 11.26 | 1.5 ± 13.74 | 5.3 ± 9.58 | 0.5 ± 14.08 | 3.5 ± 10.24 |
| Week 11 - Day 74 | -12.3 ± 17.76 | -4.0 ± 15.26 | 2.7 ± 13.46 | 3.1 ± 10.87 | 2.7 ± 10.22 | 3.2 ± 15.48 |
| Week 12 - Day 78 | -9.0 ± 19.23 | 1.4 ± 11.06 | -1.3 ± 12.82 | -1.0 ± 10.26 | -3.2 ± 5.93 | -2.7 ± 10.19 |
| Week 12 - Day 81 | -9.8 ± 16.05 | -4.4 ± 10.61 | 1.2 ± 11.32 | 4.2 ± 13.13 | -1.8 ± 6.66 | 1.9 ± 13.10 |
| Week 13 - Day 85 | -14.1 ± 18.48 | -4.6 ± 7.28 | -0.9 ± 11.56 | 4.9 ± 10.58 | 1.9 ± 14.25 | 0.3 ± 10.24 |
| Week 13 - Day 88 | -13.6 ± 19.10 | -8.7 ± 10.14 | 0.9 ± 8.86 | 5.2 ± 12.42 | -1.0 ± 6.74 | 0.4 ± 12.20 |
| Week 14 - Day 92 | -13.6 ± 16.15 | -5.4 ± 8.34 | 1.0 ± 12.40 | 3.3 ± 10.69 | -5.2 ± 9.09 | -0.1 ± 9.52 |
| Week 14 - Day 95 | -10.6 ± 21.17 | -1.9 ± 10.27 | -1.8 ± 8.95 | -4.1 ± 9.56 | -0.9 ± 5.08 | 2.1 ± 13.09 |
Observed urine concentration of KLK1 throughout the treatment period.
| ng/mL | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort I: 2 ug/kg DM199I | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Baseline | 37.51 ± 50.024 | 17.90 ± 16.384 | 26.63 ± 35.421 | 32.48 ± 44.940 | 35.31 ± 40.090 | 21.69 ± 32.493 |
| Day 1, 2 Hours | 24.74 ± 31.925 | 12.53 ± 9.865 | 27.49 ± 38.091 | 32.22 ± 51.916 | 34.58 ± 55.209 | 34.64 ± 69.767 |
| Day 1, 4 Hours | 30.94 ± 38.879 | 15.64 ± 15.816 | 25.43 ± 32.733 | 28.87 ± 44.087 | 42.23 ± 68.623 | 32.51 ± 49.200 |
| Week 2 | 21.26 ± 15.693 | 21.89 ± 16.692 | 27.56 ± 28.259 | 31.43 ± 30.060 | 45.48 ± 55.697 | 23.95 ± 39.985 |
| Week 3 | 23.43 ± 20.694 | 24.63 ± 20.665 | 39.28 ± 53.137 | 35.03 ± 37.294 | 55.91 ± 67.072 | 21.16 ± 27.850 |
| Week 4 | 24.81 ± 19.940 | 23.06 ± 19.609 | 53.45 ± 89.031 | 26.19 ± 24.657 | 36.17 ± 47.451 | 19.80 ± 22.428 |
| Week 8 | 16.59 ± 16.383 | 29.17 ± 14.065 | 39.62 ± 39.210 | 25.88 ± 28.419 | 44.44 ± 46.799 | 28.89 ± 50.670 |
| Week 12 | 19.31 ± 14.220 | 19.30 ± 19.239 | 34.72 ± 43.353 | 22.09 ± 24.039 | 63.62 ± 112.996 | 34.18 ± 44.742 |
| Day 95 | 15.64 ± 13.171 | 21.97 ± 11.669 | 32.13 ± 32.107 | 25.58 ± 31.913 | 61.37 ± 75.390 | 17.86 ± 23.381 |
| Day 99 | 20.26 ± 16.104 | 20.17 ± 10.382 | 33.46 ± 42.561 | 18.14 ± 20.265 | 37.89 ± 41.710 | 13.58 ± 18.308 |
| Day 100 | 11.60 ± 12.750 | 17.53 ± 11.568 | 27.61 ± 34.126 | 19.74 ± 16.520 | 33.18 ± 33.675 | 16.30 ± 21.186 |
| Day 102 | 9.16 ± 7.801 | 21.20 ± 18.477 | 34.52 ± 31.006 | 18.66 ± 22.562 | 43.68 ± 47.515 | 21.45 ± 28.939 |
| Day 104 | 17.17 ± 10.770 | 37.43 ± 54.487 | 46.92 ± 57.510 | 30.71 ± 50.489 | 80.67 ± 138.158 | 40.43 ± 73.514 |
Observed KLK1 concentration throughout the treatment period.
| ng/mL | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort I: 2 ug/kg DM199I | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Baseline | 3.0909 ± 5.01327 | 1.2133 ± 2.42587 | 3.1077 ± 4.62776 | 0.8775 ± 1.93829 | 0.7500 ± 1.39202 | 2.0558 ± 3.34727 |
| Day 1, 2 Hours | 2.1146 ± 3.58565 | 1.7047 ± 2.42461 | 3.4808 ± 4.90671 | 1.4842 ± 1.79766 | 1.2551 ± 2.52952 | 3.2989 ± 3.72430 |
| Day 1, 4 Hours | 2.2868 ± 3.58380 | 2.1045 ± 2.62904 | 3.7485 ± 4.67305 | 1.3269 ± 0.93846 | 1.3779 ± 2.52956 | 3.3180 ± 3.67831 |
| Week 2 | 2.9117 ± 3.84132 | 6.2710 ± 4.02885 | 3.8417 ± 2.75541 | 4.8071 ± 3.07238 | 1.8441 ± 1.93196 | 5.7693 ± 4.49985 |
| Week 3 | 2.2178 ± 1.33780 | 5.3430 ± 4.26720 | 3.8708 ± 3.12469 | 4.6389 ± 2.19267 | 1.6892 ± 1.67998 | 6.9004 ± 4.99114 |
| Week 4 | 2.0375 ± 1.39895 | 5.6896 ± 4.58797 | 3.5852 ± 2.98440 | 4.2348 ± 2.95071 | 1.8121 ± 2.46581 | 7.3027 ± 4.77157 |
| Week 8 | 1.8525 ± 0.82422 | 4.5991 ± 4.14188 | 3.7705 ± 3.58396 | 4.4250 ± 3.33991 | 1.4225 ± 1.26179 | 6.2775 ± 4.41415 |
| Week 12 | 2.0000 ± 1.89049 | 3.2071 ± 2.51513 | 3.4816 ± 3.29190 | 3.5169 ± 2.48606 | 1.9474 ± 2.62553 | 5.9806 ± 4.90394 |
| Day 95 | 2.2189 ± 2.13775 | 4.1067 ± 2.40233 | 3.3046 ± 2.91556 | 4.2130 ± 3.61280 | 1.9837 ± 2.71757 | 5.4063 ± 4.78979 |
| Day 99 | 1.7450 ± 1.63776 | 2.7533 ± 2.40265 | 3.5395 ± 2.99486 | 2.9776 ± 3.34871 | 1.4749 ± 2.97254 | 5.5500 ± 4.55581 |
| Day 100 | 1.3625 ± 1.58327 | 2.9280 ± 2.13630 | 2.3614 ± 2.17999 | 2.4288 ± 3.31679 | 0.8899 ± 0.75772 | 4.6521 ± 4.17552 |
| Day 102 | 1.2020 ± 1.67347 | 1.6486 ± 1.23594 | 3.1495 ± 3.38345 | 1.8563 ± 3.14310 | 0.3166 ± 0.17613 | 4.3348 ± 4.51474 |
| Day 104 | 1.0423 ± 1.49716 | 0.8484 ± 0.63239 | 2.1383 ± 2.14216 | 1.4505 ± 2.91155 | 0.3158 ± 0.22805 | 2.8327 ± 3.94124 |
Tumor Necrosis Factor Receptor 1 (TNF-R1) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
| ug/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | -0.12 ± 0.274 | -0.02 ± 0.291 | 0.12 ± 0.231 | -0.15 ± 0.284 | -0.01 ± 0.272 | -0.03 ± 0.317 |
| Week 8 | 0.13 ± 0.309 | 0.11 ± 0.196 | 0.28 ± 0.344 | -0.10 ± 0.327 | -0.05 ± 0.362 | -0.15 ± 0.283 |
| Week 12 | -0.01 ± 0.145 | 0.07 ± 0.234 | 0.23 ± 0.314 | -0.18 ± 0.249 | -0.02 ± 0.270 | -0.04 ± 0.417 |
| Week 14 | 0.02 ± 0.228 | 0.18 ± 0.084 | 0.21 ± 0.397 | -0.12 ± 0.199 | -0.03 ± 0.255 | -0.07 ± 0.408 |
C-Reactive Protein (CRP) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
| nmol/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | 3.1430 ± 51.84349 | 9.0478 ± 39.93348 | 5.8731 ± 13.32043 | -13.5935 ± 24.19950 | 28.5719 ± 87.84903 | -10.4129 ± 54.56484 |
| Week 8 | -5.9524 ± 39.18178 | 53.1439 ± 143.65971 | 44.4452 ± 67.06411 | -13.0478 ± 29.24145 | -12.2621 ± 20.79303 | -16.4884 ± 71.63561 |
| Week 12 | -6.6668 ± 26.73095 | -5.0000 ± 42.29579 | 137.5423 ± 445.21130 | -6.8782 ± 17.08213 | -8.7076 ± 25.57443 | -19.1671 ± 62.96485 |
| Week 14 | -7.5001 ± 33.21677 | 16.1908 ± 45.50023 | 40.0801 ± 123.03326 | -13.8096 ± 29.12155 | -2.9841 ± 18.51273 | 14.7028 ± 110.90787 |
Matrix Metalloproteainase-9 (MMP-9) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Matrix Metalloproteinase-9 (MMP-9) was measured throughout the treatment period as a biomarker of extracellular matrix remodeling, inflammation, and tissue injury. MMP-9 is a member of the matrix metalloproteinase family of enzymes that degrade components of the extracellular matrix and play a critical role in physiological and pathological processes, including wound healing, immune cell migration, vascular remodeling, fibrosis, and inflammatory responses. Elevated MMP-9 levels have been associated with various disease states, including chronic kidney disease, cardiovascular disease, inflammatory disorders, and conditions characterized by tissue damage and remodeling.
| ug/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | 17.26 ± 108.145 | -0.49 ± 14.647 | 9.29 ± 240.618 | -22.82 ± 81.174 | -60.87 ± 166.031 | 29.80 ± 117.822 |
| Week 8 | 10.30 ± 78.654 | -16.72 ± 43.999 | -10.17 ± 66.284 | -31.84 ± 95.925 | -34.14 ± 153.432 | -1.88 ± 38.444 |
| Week 12 | 8.59 ± 72.381 | -47.85 ± 95.502 | 20.43 ± 224.725 | -38.30 ± 106.441 | 1.05 ± 44.665 | 63.24 ± 165.204 |
| Week 14 | -3.38 ± 65.663 | 2.88 ± 28.374 | -40.60 ± 182.660 | -30.99 ± 98.844 | -35.44 ± 165.781 | -6.85 ± 30.198 |
Vascular Endothelial Growth Factor (VEGF) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
| ng/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | -22.55 ± 88.842 | -3.41 ± 39.485 | -12.25 ± 80.532 | 1.05 ± 26.077 | -16.92 ± 29.600 | -0.38 ± 20.885 |
| Week 8 | -48.66 ± 76.202 | 43.21 ± 61.846 | -33.77 ± 65.351 | 3.67 ± 15.051 | 4.45 ± 26.689 | -0.21 ± 23.564 |
| Week 12 | -37.42 ± 75.241 | -21.77 ± 77.284 | -14.46 ± 31.225 | -2.36 ± 19.793 | 15.50 ± 30.087 | 15.98 ± 17.451 |
| Week 14 | -5.28 ± 62.972 | 25.50 ± 15.556 | 4.43 ± 41.063 | -8.88 ± 17.245 | 4.63 ± 44.376 | 3.81 ± 13.884 |
Cystatin C concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.
| ug/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | -147.77 ± 661.456 | -82.53 ± 278.848 | 36.59 ± 428.227 | -91.22 ± 422.600 | -142.87 ± 964.978 | 19.86 ± 910.209 |
| Week 8 | 121.63 ± 916.429 | -1.99 ± 680.486 | 190.72 ± 758.873 | 125.80 ± 689.210 | 66.74 ± 775.026 | -50.43 ± 654.957 |
| Week 12 | -388.97 ± 754.844 | 11.52 ± 285.072 | 244.88 ± 470.071 | -136.93 ± 685.749 | -31.22 ± 705.663 | -84.49 ± 1015.488 |
| Week 14 | -172.68 ± 769.966 | 142.64 ± 715.372 | 305.55 ± 518.979 | 7.23 ± 674.078 | -59.44 ± 689.961 | -233.23 ± 823.811 |
Prostaglandin E2 concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostaglandin E2 is a biomarker of inflammatory activity, immune regulation, and physiological processes involved in vascular and renal function. PGE2 is a bioactive lipid mediator derived from arachidonic acid through the cyclooxygenase (COX) pathway and is produced by a variety of cell types in response to inflammatory stimuli, tissue injury, and other physiological signals. PGE2 plays an important role in modulating inflammation, vasodilation, blood flow regulation, immune responses, and maintenance of normal kidney function.
| ng/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | 93.22 ± 279.780 | 254.77 ± 767.177 | 185.96 ± 477.878 | 586.65 ± 1542.503 | -92.33 ± 515.393 | -196.74 ± 1148.824 |
| Week 8 | 57.53 ± 204.382 | 170.72 ± 712.769 | 182.10 ± 416.398 | 707.04 ± 1759.144 | -223.01 ± 881.133 | -185.41 ± 1060.557 |
| Week 12 | 39.91 ± 229.710 | 405.02 ± 733.275 | 402.95 ± 683.799 | 670.32 ± 1643.506 | -262.08 ± 866.935 | -222.32 ± 1140.811 |
| Week 14 | 672.47 ± 1319.356 | 65.86 ± 179.093 | 454.15 ± 960.015 | 596.23 ± 1403.538 | -51.92 ± 910.307 | 14.18 ± 1665.939 |
Prostacyclin concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostacyclin is a biomarker of vascular function, endothelial health, and regulation of platelet activity. Prostacyclin, also known as prostaglandin I2 (PGI2), is a biologically active lipid mediator produced primarily by vascular endothelial cells through the cyclooxygenase pathway. It plays a critical role in maintaining vascular homeostasis by promoting vasodilation, inhibiting platelet aggregation, and helping to regulate blood flow and vascular tone. Prostacyclin is also involved in modulating inflammatory responses and protecting against the development of thrombosis and vascular injury.
| ng/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | -13.08 ± 29.220 | 15.60 ± 29.468 | 1.99 ± 15.130 | 6.09 ± 43.526 | -4.13 ± 35.410 | 1.68 ± 33.930 |
| Week 8 | -19.29 ± 23.985 | -5.10 ± 47.130 | 15.48 ± 36.181 | 11.09 ± 22.339 | 4.93 ± 37.279 | 6.49 ± 28.535 |
| Week 12 | -25.17 ± 25.386 | 10.20 ± 29.095 | 26.48 ± 43.596 | 13.25 ± 46.781 | 2.98 ± 29.068 | 2.53 ± 31.487 |
| Week 14 | 2.47 ± 48.420 | 14.60 ± 36.185 | 21.76 ± 29.081 | 18.63 ± 36.747 | 2.93 ± 32.418 | -6.69 ± 50.053 |
Kidney Injury Molecule-1 (KIM-1) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.
| ng/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | 236.01 ± 1060.149 | 192.50 ± 689.877 | 43.21 ± 576.908 | -293.90 ± 751.931 | -463.36 ± 1560.340 | 11.77 ± 898.226 |
| Week 8 | -215.47 ± 503.815 | 180.34 ± 360.329 | 309.51 ± 1503.507 | -345.98 ± 573.113 | -194.27 ± 1010.344 | 294.28 ± 1071.373 |
| Week 12 | -107.59 ± 483.736 | 283.38 ± 286.078 | -92.63 ± 799.761 | -195.48 ± 730.647 | -623.04 ± 1165.895 | 789.43 ± 1077.718 |
| Week 14 | -104.48 ± 297.454 | -71.38 ± 342.880 | -177.55 ± 1045.979 | -87.97 ± 756.976 | 219.30 ± 1481.125 | 443.71 ± 1044.764 |
Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.
| ug/L | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Week 4 | -26.98 ± 43.359 | 49.76 ± 222.701 | -9.48 ± 245.484 | 2.84 ± 148.485 | -33.65 ± 66.059 | -21.71 ± 97.002 |
| Week 8 | -21.93 ± 40.289 | 1.29 ± 97.210 | -34.02 ± 225.233 | -51.84 ± 95.887 | -34.30 ± 124.384 | -38.94 ± 68.383 |
| Week 12 | 10.44 ± 90.799 | -9.56 ± 136.828 | -37.27 ± 253.220 | -85.75 ± 125.603 | -53.73 ± 120.154 | 34.64 ± 194.382 |
| Week 14 | 5.48 ± 71.887 | -66.53 ± 105.157 | -60.78 ± 226.990 | -50.24 ± 121.014 | -55.81 ± 94.272 | -48.21 ± 107.276 |
Collected over From first dose on Day 1 through Day 104. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I: 2 ug/kg DM199 | 0/11 (0%) | 2/11 (18.2%) | 7/11 (63.6%) |
| Cohort I: 5 ug/kg DM199 | 1/12 (8.3%) | 1/12 (8.3%) | 10/12 (83.3%) |
| Cohort II: 2 ug/kg DM199 | 0/13 (0%) | 2/13 (15.4%) | 7/13 (53.8%) |
| Cohort II: 5 ug/kg DM199 | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Cohort III: 2 ug/kg DM199 | 0/17 (0%) | 2/17 (11.8%) | 6/17 (35.3%) |
| Cohort III: 5 ug/kg DM199 | 0/17 (0%) | 4/17 (23.5%) | 10/17 (58.8%) |
| Event | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/11 | 0/12 | 0/13 | 0/12 | 1/17 | 2/17 |
| Acute myocardial infarctionCardiac disorders | 1/11 | 0/12 | 0/13 | 0/12 | 0/17 | 1/17 |
| Hypertensive urgencyVascular disorders | 1/11 | 0/12 | 0/13 | 0/12 | 0/17 | 0/17 |
| HypotensionVascular disorders | 1/11 | 0/12 | 0/13 | 0/12 | 0/17 | 0/17 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/11 | 0/12 | 0/13 | 0/12 | 0/17 | 0/17 |
| DeathGeneral disorders | 0/11 | 1/12 | 0/13 | 0/12 | 0/17 | 0/17 |
| Atrial fibrillationCardiac disorders | 0/11 | 0/12 | 1/13 | 0/12 | 0/17 | 1/17 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/11 | 0/12 | 1/13 | 0/12 | 0/17 | 1/17 |
| COVID-19 pneumoniaInfections and infestations | 0/11 | 0/12 | 1/13 | 0/12 | 0/17 | 0/17 |
| Cardiac failure congestiveCardiac disorders | 0/11 | 0/12 | 0/13 | 0/12 | 1/17 | 0/17 |
| Event | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 1/11 | 3/12 | 2/13 | 6/12 | 3/17 | 2/17 |
| Injection site erythemaGeneral disorders | 1/11 | 1/12 | 2/13 | 5/12 | 2/17 | 3/17 |
| HypertensionVascular disorders | 4/11 | 1/12 | 3/13 | 1/12 | 2/17 | 3/17 |
| Injection site swellingGeneral disorders | 0/11 | 2/12 | 1/13 | 2/12 | 1/17 | 2/17 |
| Injection site bruisingGeneral disorders | 0/11 | 0/12 | 1/13 | 2/12 | 1/17 | 0/17 |
| Injection site pruritusGeneral disorders | 1/11 | 1/12 | 2/13 | 1/12 | 0/17 | 0/17 |
| SinusitisInfections and infestations | 0/11 | 0/12 | 2/13 | 0/12 | 0/17 | 0/17 |
| HypokalaemiaMetabolism and nutrition disorders | 0/11 | 0/12 | 2/13 | 0/12 | 0/17 | 1/17 |
| PneumoniaInfections and infestations | 0/11 | 0/12 | 0/13 | 0/12 | 1/17 | 2/17 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/11 | 0/12 | 0/13 | 0/12 | 2/17 | 2/17 |
\[1\] Safety Population: All participants who have received any amount of study drug. Participants are summarized according to the dose received. Demographic, baseline characteristics, urinary concentration of KLK1, and safety and tolerability analyses were conducted using the Safety Population. \[2\] Participants 07-310 and 14-101 were randomized but not treated (and excluded from the Safety Population) because they were lost to follow-up and had a Covid infection respectively.
| Age, Continuous(Years) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 51.5 ± 12.66 | 60.0 ± 13.79 | 51.2 ± 12.19 | 46.5 ± 9.81 | 63.2 ± 9.33 | 68.4 ± 7.18 | 57.9 ± 13.03 |
| Sex: Female, Male(Participants) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 8 | 5 | 3 | 8 | 6 | 32 |
| Male | 9 | 4 | 8 | 9 | 9 | 11 | 50 |
| Race/Ethnicity, Customized(Participants) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| White | 0 | 0 | 11 | 10 | 11 | 7 | 39 |
| Black or African American | 11 | 12 | 1 | 0 | 4 | 8 | 36 |
| Asian | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Other | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73m^2) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 50.04 ± 17.593 | 50.50 ± 22.584 | 46.55 ± 17.275 | 49.95 ± 19.629 | 49.19 ± 16.850 | 41.95 ± 13.609 | 47.69 ± 17.520 |
| Urine Albumin Creatinine Ratio (UACR)(g/kg) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 805.66 ± 968.520 | 656.57 ± 761.442 | 1001.35 ± 857.728 | 741.20 ± 442.423 | 1051.47 ± 893.229 | 1371.56 ± 1513.248 | 971.77 ± 1003.196 |
| Systolic Blood Pressure(mmHg) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 148.0 ± 30.51 | 143.2 ± 18.47 | 131.0 ± 11.24 | 126.3 ± 13.39 | 139.0 ± 11.73 | 144.8 ± 14.07 | 138.9 ± 18.04 |
| Diastolic Blood Pressure(mmHg) | Cohort I: 2 ug/kg DM199 | Cohort I: 5 ug/kg DM199 | Cohort II: 2 ug/kg DM199 | Cohort II: 5 ug/kg DM199 | Cohort III: 2 ug/kg DM199 | Cohort III: 5 ug/kg DM199 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 92.4 ± 16.57 | 85.7 ± 9.66 | 83.5 ± 8.27 | 81.2 ± 11.78 | 80.3 ± 6.13 | 78.5 ± 6.32 | 83.0 ± 10.50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Mar 2022, 26 months.
Results were first posted in Nov 2026, 4 years 7 months after primary completion.
Of 41 phase 2 interventional studies under Kidney Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DM199
DiaMedica Therapeutics Inc